Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children

A Phase 2B, Open-label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Effectiveness of Hydrocodone Bitartrate Extended-Release Tablets (HYD) in Children, Aged 12 to 17 Years Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Around-the-Clock Opioid Analgesics

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and effectiveness of Hydrocodone Bitartrate (HYD) tablets in children with moderate to severe pain requiring around-the-clock opioid analgesics.

Study Overview

• Status: Withdrawn
• Conditions: Pain
• Intervention / Treatment: Drug: HYD tablets

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 17 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria include:

1. Males and females, aged 12 to 17 years, with pain severe enough to require daily, around-the-clock opioid treatment at a dose equivalent to at least 20 mg daily of hydrocodone for at least 2 weeks.
2. Patients must have stable vital signs and hemoglobin oxygen saturation, eg, measured by pulse oximetry (SpO2).
3. Patients must be willing and able to swallow medicinal tablets.
4. Female patients of childbearing potential must have a negative pregnancy test within 24 hours prior to the start of study drug treatment.
5. Female patients who are sexually active must be using (and continue using throughout the study) an acceptable method of birth control, per investigator's discretion.
6. Patients and patient's parent/caregiver must be compliant with the protocol, ie, must be able to perform study assessments and understand and complete the age-appropriate scale to rate pain intensity.
7. Patients must not have a cognitive developmental delay or any other condition that would preclude them from completing the age-appropriate pain scale.

Exclusion Criteria include:

1. Patients who require a starting total daily dose of HYD > 120 mg.
2. Patients who have had surgery within 72 hours prior to the start of study drug treatment.
3. Patients who have any planned surgery during the study will be excluded.
4. Female patients who are pregnant or lactating.
5. Patients who are allergic to hydrocodone or any other component of HYD or have a history of allergies to other opioids.
6. Patients who receive or are expected to receive an investigational drug/therapy during the study drug treatment or follow-up period.
7. Patients who are anticipated to receive any hydrocodone- or hydromorphone-containing products (other than study drug) during the study or 3 days prior to initiation of treatment with study drug.
8. Patients with a history of alcohol, medication, or illicit drug abuse or addiction and/or opioid abuse or addiction at any time.
9. Patients with contraindication to blood sampling.

Other protocol-specific inclusion/exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HYD 20 - 120 mg; Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours	Drug: HYD tablets; Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.; Other Names: Hysingla® ER

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The number of participants with adverse events as a measure of safety	Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment).
Pharmacokinetic analysis to characterize the apparent volume of distribution (Vc/F) of hydrocodone following oral administration	Day 1, End of week 2, End of week 4
Pharmacokinetic analysis to characterize the apparent oral clearance (CL/F) of hydrocodone following oral administration	Day 1, End of week 2, End of week 4

Secondary Outcome Measures

Outcome Measure	Time Frame
"Pain Right Now" Assessment by Patients using 100-mm visual analog scale (VAS)	Day 1 up to week 4
Parent/ Caregiver-Assessed Global Impression of Change (PGIC)	Week 4 / end of treatment

Collaborators and Investigators

• Sponsor: Purdue Pharma LP

Publications and helpful links

Helpful Links

• Product Information

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2017
• Primary Completion (Anticipated): July 1, 2019
• Study Completion (Anticipated): July 1, 2019

Study Registration Dates

• First Submitted: August 27, 2015
• First Submitted That Met QC Criteria: September 2, 2015
• First Posted (Estimate): September 4, 2015

Study Record Updates

• Last Update Posted (Actual): April 24, 2017
• Last Update Submitted That Met QC Criteria: April 21, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Respiratory System Agents; Antitussive Agents; Hydrocodone
• Other Study ID Numbers: HYD4002